Martine Piccart, MD, PhD & Head of the Medicine Department at the Jules Bordet Institute and Co-Founder of the Breast International Group (BIG) discusses primary analysis of the EORTC 10041/BIG 3-04 MINDACT study: A prospective, randomized study evaluating the clinical utility of the 70-gene signature (MammaPrint) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes at the American Association of Cancer Research Annual Meeting 2016 (AACR16).
MDLinx Conference Coverage - American Association of Cancer Research Annual Meeting 2016: [ Ссылка ]
MDLinx: [ Ссылка ]
Smartest Doc & Board Exam Prep: [ Ссылка ]
M3 USA: [ Ссылка ]
Follow MDLinx:
Facebook - [ Ссылка ]
Twitter - [ Ссылка ]
Google+ - [ Ссылка ]
